0001140361-23-051737.txt : 20231107 0001140361-23-051737.hdr.sgml : 20231107 20231107081543 ACCESSION NUMBER: 0001140361-23-051737 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231107 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231107 DATE AS OF CHANGE: 20231107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nuwellis, Inc. CENTRAL INDEX KEY: 0001506492 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 680533453 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35312 FILM NUMBER: 231381790 BUSINESS ADDRESS: STREET 1: 12988 VALLEY VIEW ROAD CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 BUSINESS PHONE: 952-345-4200 MAIL ADDRESS: STREET 1: 12988 VALLEY VIEW ROAD CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 FORMER COMPANY: FORMER CONFORMED NAME: CHF Solutions, Inc. DATE OF NAME CHANGE: 20170523 FORMER COMPANY: FORMER CONFORMED NAME: Sunshine Heart, Inc. DATE OF NAME CHANGE: 20101124 8-K 1 ef20014069_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2023

Nuwellis, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware
001-35312
No. 68-0533453
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File Number)
(I.R.S. Employer Identification No.)

12988 Valley View Road, Eden Prairie, MN 55344
(Address of Principal Executive Offices) (Zip Code)

(952) 345-4200
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NUWE
Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition.

On November 7, 2023, Nuwellis, Inc. (the “Company”) issued a press release reporting its financial results for the three and nine months ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information included in this Current Report on Form 8-K (including Exhibit 99.1) is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Item 9.01
Financial Statements and Exhibits.

  (d) Exhibits

Exhibit No. Description

Press Release, dated November 7, 2023, reporting the financial results of Nuwellis, Inc. for the three and nine months ended September 30, 2023.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2023
  
NUWELLIS, INC.
     
 
By:
/s/ Nestor Jaramillo, Jr.
  
 
Name:
Nestor Jaramillo, Jr.
  
 
Title:
President and Chief Executive Officer



EX-99.1 2 ef20014069_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1


Nuwellis, Inc. Announces Third Quarter 2023 Financial Results

Minneapolis, MN, November 7, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2023.


 •
Revenue of $2.4 million for the third quarter 2023, increased 16% over the prior quarter and increased 17% over the prior-year period.

•
Therapy utilization, or the number of circuits per placed console, increased 26% over the prior year, reflecting continued increases in the number of patients treated with the Aquadex® therapy.

•
By customer category, third quarter 2023 revenue in Heart Failure increased 27% over the same period last year, Critical Care and Pediatrics increased 16% and 9%, respectively.

•
Despite continuing hospital capital budget constraints, our installed console base increased. In the third quarter, we sold 20 consoles, an increase of 11 units vs prior quarter.

“Our 17% annual revenue growth in the third quarter was driven by steady progress on our key strategic initiatives, including leveraging our growing body of clinical evidence to increase the number of patients treated with the Aquadex Ultrafiltration System.  We believe these efforts drove both adoption and growth, with a 26% increase in therapy utilization and continued revenue growth across all customer categories.” said Nestor Jaramillo, Jr., President and CEO of Nuwellis. “In addition to the strong sales results, we are very excited with our two strategic collaborations with SeaStar and DaVita. We congratulate SeaStar on its recent receipt of an Approvable Letter from the FDA for its Pediatric SCD device, as to which we have exclusive U.S. distribution rights. We continue to make progress in the pilot phase of our Supply and Collaboration Agreement with DaVita. With focused execution across multiple growth levers, our team is committed to make Aquadex ultrafiltration therapy the new standard of care for fluid overload patients resistant to diuretics,” concluded Mr. Jaramillo.

Third Quarter 2023 Financial Results

Revenue for the third quarter of 2023 was $2.4 million, a 17% growth over the prior-year period. Results in the quarter were driven by a 26% increase in circuit sales.

Gross margin was 57.3% for the third quarter of 2023, compared to 61.0% in the prior-year period. The decline in gross margin was primarily driven by lower console manufacturing volumes. US disposable product margins are 74.0% which are in-line with medical technology industry standards.

Selling, general and administrative expenses for the third quarter of 2023 were $3.4 million, compared to $4.2 million in the prior-year period. The $800,000 decrease was primarily due to reduced headcount and related compensation expense.

Third quarter research and development expenses were $1.1 million, compared to $928 thousand in the third quarter of 2022, reflecting a modest increase in spend related to the final phases of the development of our new pediatric dedicated CRRT device as we approach IDE submission.

Total operating expense of $4.5 million was down 12% year over year and down 26% sequentially; due to cost saving measures implemented early in Q3.

Net loss for the third quarter of 2023 was $3.4 million, or a loss of $1.81 per share, compared to a net loss of $3.9 million, or a loss of $36.72 per common share, in the prior-year period. The decrease in net loss per share is due to an increase in sales, lower spend, and an increase in weighted average share count.

At September 30, 2023, the Company had no debt and cash and cash equivalents of $4.9 million, with approximately 1.9 million common shares outstanding.  On October 17, Nuwellis closed an underwritten public offering with gross proceeds of $2.25 million before deducting underwriting discounts and commissions related to the offering.

Webcast and Conference Call Information
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the company’s performance.

To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using the conference ID: 10182705. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minnesota with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn.

About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible, and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg. or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2023 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS

INVESTORS:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com

NUWELLIS, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)

   
September 30,
2023
    
December 31,
2022
  
ASSETS
  
(unaudited)
        
Current assets
            
Cash and cash equivalents
  
$
4,930
    
$
17,737
  
Marketable securities
    
—
      
569
  
Accounts receivable
    
1,425
      
1,406
  
Inventories, net
    
2,336
      
2,661
  
Other current assets
    
947
      
396
  
Total current assets
    
9,638
      
22,769
  
Property, plant and equipment, net
    
912
      
980
  
Operating lease right-of-use asset
    
762
      
903
  
Other assets
    
120
      
21
  
TOTAL ASSETS
  
$
11,432
    
$
24,673
  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities
                
Accounts payable and accrued liabilities
  
$
1,707
    
$
2,245
  
Accrued compensation
    
1,021
      
2,161
  
Current portion of operating lease liability
    
211
      
196
  
Current portion of finance lease liability
    
8
      
28
  
Other current liabilities
    
45
      
58
  
Total current liabilities
    
2,992
      
4,688
  
Common stock warrant liability
    
—
      
6,868
  
Operating lease liability
    
601
      
760
  
Total liabilities
    
3,593
      
12,316
  
                 
Commitments and contingencies
                
                 
Stockholders’ equity
                
Series A junior participating preferred stock as of September 30, 2023 and December 31, 2022, par value $0.0001 per share; authorized 30,000 shares, none outstanding
    
—
      
—
  
Series F convertible preferred stock as of both September 30, 2023 and December 31, 2022, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares
    
—
      
—
  
Series I convertible preferred stock as of September 30, 2023 and December 31, 2022, par value $0.0001; authorized 1,049,280, issued and outstanding none and 1,049,280, respectively
                
Preferred stock as of both September 30, 2023 and December 31, 2022, par value $0.0001 per share; authorized 39,969,873 shares, none outstanding
    
—
      
—
  
Common stock as of September 30, 2023 and December 31, 2022, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 1,864,265 and 536,394 shares, respectively
    
—
        
—
  
Additional paid-in capital
    
289,980
      
279,736
  
Accumulated other comprehensive income:
                
Foreign currency translation adjustment
    
(24
)
    
(18
)
Unrealized gain on marketable securities
    
—
       56
  
Accumulated deficit
    
(282,117
 )    
(267,417
)
Total stockholders’ equity
    
7,839
      
12,357
  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
   $
11,432
     $
24,673
  

See notes to the condensed consolidated financial statements.

NUWELLIS, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except per share amounts)

   
Three months ended
September 30
    
Nine months ended
September 30
  
   
2023
    
2022
    
2023
    
2022
  
Net sales
  
$
2,412
    
$
2,065
    
$
6,313
    
$
6,204
  
Cost of goods sold
    
1,031
      
806
      
2,718
      
2,780
  
Gross profit
    
1,381
      
1,259
      
3,595
      
3,424
  
Operating expenses:
                                
Selling, general and administrative
    
3,428
      
4,251
      
13,582
      
12,920
  
Research and development
    
1,117
      
928
      
4,050
      
3,141
  
Total operating expenses
    
4,545
      
5,179
      
17,632
      
16,061
  
Loss from operations
    
(3,164
)
    
(3,920
)
    
(14,037
)
    
(12,637
)
Other income (expense), net
    
(204
)
    
52
      
98
      
14
  
Change in fair value of warrant liability
    
—
      
—
      
(755
)
    
—
  
Loss before income taxes
    
(3,368
)
    
(3,868
)
    
(14,694
)
    
(12,623
)
Income tax expense
    
(2
)
    
(2
)
    
(6
)
    
(6
)
Net loss
  
$
(3,370
)
  
$
(3,870
)
  
$
(14,700
)
  
$
(12,629
)
                                 
Basic and diluted loss per share
  
$
(1.81
)
  
$
(36.72
)
  
$
(10.21
)
  
$
(119.85
)
                                 
Weighted average shares outstanding – basic and diluted
    
1,864
      
105
      
1,439
      
105
  
                                 
Other comprehensive loss:
                                
Foreign currency translation adjustments
  
$
—
    
$
2
    
$
(6
)
  
$
1
  
Total comprehensive loss
  
$
(3,370
)
  
$
(3,868
)
  
$
(14,706
)
  
$
(12,628
)

See notes to the condensed consolidated financial statements.
 
NUWELLIS, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)

   
Nine months ended
September 30
  
   
2023
    
2022
  
Operating Activities:
            
Net loss
  
$
(14,700
)
  
$
(12,629
)
Adjustments to reconcile net loss to cash flows used in operating activities:
                
Depreciation and amortization
    
253
      
301
  
Stock-based compensation expense, net
    
513
      
697
  
Change in fair value of warrant liability
    
755
      
—
  
Net realized gain on marketable securities
    
(65
)
    
—
  
Changes in operating assets and liabilities:
                
Accounts receivable
    
(19
)
    
(350
)
Inventory, net
     325      
(113
)
Other current assets
    
(551
)
    
(40
)
Other assets and liabilities
    
(16
)
    
(142
)
Accounts payable and accrued expenses
    
(1,678
)
    
254
  
Net cash used in operating activities
    
(15,183
)
    
(12,022
)
                 
Investing Activities:
                
Proceeds from sale of marketable securities
    
578
      
—
  
Additions to intangible assets
    
(99
)
    
—
  
Purchases of property and equipment
    
(185
)
    
(103
)
Net cash provided by (used in) investing activities
    
294
      
(103
)
                 
Financing Activities:
                
Proceeds from ATM stock offerings, net
    
2,108
      
—
  
Payments on finance lease liability
    
(20
)
    
(28)
  
Net cash provided by (used in) financing activities
    
2,088
      
(28
)
                 
Effect of exchange rate changes on cash
    
(6
)
    
1
  
Net decrease in cash and cash equivalents
    
(12,807
)
    
(12,152
)
Cash and cash equivalents - beginning of period
    
17,737
      
24,205
  
Cash and cash equivalents - end of period
  
$
4,930
    
$
12,053
  
                 
Supplemental cash flow information  
 
          
Inventory transferred to property, plant and equipment   $ —     $ 37
 
Non-cash impact of conversion of warrants to common stock (see Note 3)   $ 6,868
    $ —
 

See notes to the condensed consolidated financial statements.


 EX-101.SCH 3 nuwe-20231107.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nuwe-20231107_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 nuwe-20231107_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00001.jpg begin 644 image00001.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 07, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 07, 2023
Entity File Number 001-35312
Entity Registrant Name Nuwellis, Inc.
Entity Central Index Key 0001506492
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 68-0533453
Entity Address, Address Line One 12988 Valley View Road
Entity Address, City or Town Eden Prairie
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55344
City Area Code 952
Local Phone Number 345-4200
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol NUWE
Security Exchange Name NASDAQ
XML 8 ef20014069_8k_htm.xml IDEA: XBRL DOCUMENT 0001506492 2023-11-07 2023-11-07 false 0001506492 NASDAQ 8-K 2023-11-07 Nuwellis, Inc. DE 001-35312 68-0533453 12988 Valley View Road Eden Prairie MN 55344 952 345-4200 Common Stock, par value $0.0001 per share NUWE false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://sunshineheart.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20014069_8k.htm nuwe-20231107.xsd nuwe-20231107_lab.xml nuwe-20231107_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20014069_8k.htm": { "nsprefix": "nuwe", "nsuri": "http://sunshineheart.com/20231107", "dts": { "inline": { "local": [ "ef20014069_8k.htm" ] }, "schema": { "local": [ "nuwe-20231107.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "nuwe-20231107_lab.xml" ] }, "presentationLink": { "local": [ "nuwe-20231107_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://sunshineheart.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20231107to20231107", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20014069_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231107to20231107", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20014069_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001140361-23-051737-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-051737-xbrl.zip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end